| Bioactivity | AB-729 sodium is a siRNA specifically designed to inhibit viral replication and reduces HBV antigens[1][2]. AB-729 conjugates to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes uptake into hepatocytes via the asialoglycoprotein receptor (ASGR). |
| Name | AB-729 sodium |
| CAS | 2826248-50-2 |
| Formula | C502H640F6N162Na38O303P38S6 |
| Molar Mass | 16148.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Efthymios P Tsounis, et al. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure. World J Gastroenterol. 2021 Jun 7;27(21):2727-2757. [2]. Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent. |
AB-729 sodium
CAS: 2826248-50-2 F: C502H640F6N162Na38O303P38S6 W: 16148.44
AB-729 sodium is a siRNA specifically designed to inhibit viral replication and reduces HBV antigens. AB-729 conjugates
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.